International Journal of Clinical Research
International Journal of Clinical Research. 2025; 9: (5) ; 10.12208/j.ijcr.20250250 .
总浏览量: 119
1 重庆医药高等专科学校附属第一医院 重庆
2 重庆市人民医院 重庆
*通讯作者： 李国熊,单位： 重庆市人民医院 重庆；
近年来，碳青霉烯类耐药菌（carbapenem-resistant organisms, CRO）的广泛传播对全球公共卫生构成了严峻挑战。作为治疗CRO所致重症感染的最后一道防线，多黏菌素类抗菌药物的临床应用及其研究进展备受瞩目。本文系统综述了多黏菌素类抗菌药物在治疗CRO所致重症感染中的最新临床研究进展，涵盖药物特性、药代动力学与药效学、临床应用策略及不良反应与安全性管理等多个维度。随着耐药机制的深入探索与新型药物的研发，多黏菌素类抗菌药物的临床应用前景广阔，有望为CRO所致重症感染的治疗提供更为有效的解决方案。
In recent years, the widespread spread of carbapenem-resistant bacteria (carbapenem-resistant organisms, CRO) has posed a severe challenge to global public health. As the last line of defense for the treatment of severe infections caused by CRO, the clinical application and research progress of polymyxin antibiotics have attracted much attention. This paper systematically reviews the latest clinical research progress of polymyxin antibiotics in the treatment of severe infections caused by CRO, including drug characteristics, pharmacokinetics and pharmacodynamics, clinical application strategy, and adverse effects and safety management. With the in-depth exploration of drug resistance mechanism and the research and development of new drugs, the clinical application prospect of polymycotin antibiotics is broad, which is expected to provide more effective solutions for the treatment of severe infection caused by CRO.
[1] 彭希,祝伟,静亮.多黏菌素E甲磺酸钠治疗多重耐药鲍曼不动杆菌肺炎的效果观察[J].保健医学研究与实践,2023, 20(10):43-46.
[2] 中国医药教育协会感染疾病专业委员会,中华医学会呼吸病学分会,中华医学会重症医学分会,中华医学会血液学分会,中华医学会细菌感染与耐药防治分会,中国药学会药物临床评价研究专业委员会,全球华人临床微生物与感染学会,刘又宁,俞云松,李健,施毅.中国多黏菌素类抗菌药物临床合理应用多学科专家共识[J].中华结核和呼吸杂志,2021,44(4):292-310.
[3] 袁宾彬,徐颖,王倩,陈丽秋,梁培,顾勤.静脉滴注联合雾化吸入多黏菌素B治疗碳青霉烯耐药革兰阴性杆菌肺炎的临床研究[J].中国呼吸与危重监护杂志,2024,23(6):390-394.
[4] 王静,辛绍斌,孙强,马旺,齐勇,王永明,申翔.以多黏菌素B为基础联合治疗耐碳青霉烯革兰阴性菌脓毒症的临床疗效分析[J].天津医药,2022,50(1):88-93.
[5] 广东省药学会,陈敏英,刘紫锰.临床重症与药学超说明书用药专家共识(2021新增版)[J].今日药学,2022,32(5):321-330.
[6] 陈慧云,陈科帆,陈杰.多黏菌素B治疗危重患者泛耐药革兰阴性菌感染的疗效和影响因素分析[J].中国医院药学杂志,2022,42(13):1357-1360.
[7] SUK P,RYCHLÍKOVÁJ.Pharmacokinetics of colistin during extracorporeal membrane oxygenation[J]. J Antimicrob Chemother, 2022, 77(8):2298-2300.
[8] 王雨,黄晓岚,张楚晗,等.液相色谱串联质谱法测定人血浆中多黏菌素B及在治疗药物监测中的应用[J].中国感染与化疗杂志,2022,22(6):694-701.
[9] 秦一,姚青青,高杰,王永,黄晨蓉,朱建国,缪丽燕,管小俊.UPLC-MS/MS测定患者血浆多黏菌素B的浓度及用药方案优化研究[J].中国医院药学杂志,2023,43(6):607-611.
[10] 许月芳,刘旺,曾妙甜,郭宇姝.多粘菌素B和多粘菌素E治疗外科多重耐药菌感染临床疗效及安全性分析[J].中华普外科手术学杂志（电子版）,2024,18(6):700-703.
[11] YENDEWA G A,GRIFFISS J M,GRAY W A,et al. Dosing colistimethate every 8 h results in higher plasma concentrations of active colistin than every 12-hourly dosing without increase in nephrotoxicity: a phase 1 pharmacokinetics trial in healthy adult volunteers[J]. Antibiotics (Basel,Switzerland),2022,11(4):490.
[12] BAO X L,TAO T,TANG N,et al. Efficacy and safety of adjunctive nebulized colistin sulfate for multidrug resistant Gram-negative bacteria pneumonia: a retrospective comparative cohort study[J]. Ann Palliat Med,2022,11(9): 2939-2951.